EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, NetraMark Holdings's enterprise value is €14.80 Mil.
NetraMark Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €0.06 Mil. Therefore, NetraMark Holdings's EV-to-Revenue for today is 246.72.
The historical rank and industry rank for NetraMark Holdings's EV-to-Revenue or its related term are showing as below:
FRA:PF0'
s EV-to-Revenue Range Over the Past 10 Years
Min: 51.98 Med: 151.68 Max: 301.6
Current: 246.69
During the past 4 years, the highest EV-to-Revenue of NetraMark Holdings was 301.60. The lowest was 51.98. And the median was 151.68.
FRA:PF0's EV-to-Revenue is ranked worse than 98.64% of 663
companies
in the Healthcare Providers & Services industry
Industry Median: 1.85
vs FRA:PF0: 246.69
The historical data trend for NetraMark Holdings's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of NetraMark Holdings's EV-to-Revenue
For the Health Information Services subindustry, NetraMark Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NetraMark Holdings's EV-to-Revenue Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, NetraMark Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where NetraMark Holdings's EV-to-Revenue falls into.
NetraMark Holdings's current Enterprise Value is €14.80 Mil.
NetraMark Holdings's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NetraMark Holdings's share price for today is €0.188.
NetraMark Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NetraMark Holdings EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of NetraMark Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
NetraMark Holdings Inc is focused on the application of a totally unique Artificial Intelligence (AI) / Machine Learning (ML) solution targeted at the pharmaceutical industry in order to de-risk clinical trials. NetraMark has a proprietary technology that is capable of cutting through the combinatorial complexity that comes with dealing with heterogeneous patient populations to extract precisely defined personas of patients with respect to placebo and drug response, in addition to tolerability and adverse events. By using the client's own contemporaneous data, and having the capacity to learn from small data, the NetraAI tech extracts these personas to equip pharmaceutical companies with strategies to optimize their next trials for success.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:PF0 has been successfully added to your 